You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Severe aortic senosis is usually defined as a valve area of ≤1.0 cm2 and a maximum velocity of ≥4.0 meters/second or mean pressure gradient ≥40 mm Hg.
Severe aortic stenosis is the result of leaflet calcification or congenital stenosis with severely reduced leaflet opening.1,2
Download the Aortic Stenosis Evolut™ TAVI Augmented
Reality Education app from the App Store and Google Play.
DOWNLOAD MARKER IMAGES FOR AORTIC STENOSIS EVOLUT™ TAVI AUGMENTED REALITY EDUCATION
Severe aortic stenosis prevents your aortic valve leaflets from opening and closing properly. This makes your heart work harder to pump blood to the rest of your body. A diseased valve affects your health and limits your daily activities.
Symptoms of severe aortic stenosis include, but may not be limited to:
Detect heart valve disease.
Attention: Low flow, low gradient (LF/LG) aortic stenosis cannot be detected by auscultation. Therefore, auscultation should not be relied on to exclude valve disease.
Detect symptoms and prognostic information during exercise.
Key diagnostic tool, which confirms aortic stenosis.
Detect aortic valve calcium load. Relevant for TAVI patient workup and pre-procedural planning.
Provide additional information beyond initial findings and is restricted to patients with inconclusive non-invasive investigations.
From the 2017 ESC/EACTS guidelines for the management of valvular heart disease3
Intervention is indicated in symptomatic patients with:
Severe, high-gradient aortic stenosis
Severe, low flow, low-gradient aortic stenosis with reduced ejection fraction and evidence of flow (contractile) reserve excluding pseudo-severe aortic stenosis.
Essential questions in the evaluation of patients for valvular intervention:
AS = Aortic Stenosis; LVFT = Left Ventricular Ejection Fraction; SAVR = Surgical Aortic Valve Replacement; TAVI = Transcatheter Aortic Valve Implantation.
a Surgery should be considered (lla C) if one of the following is present: peak velocity > 5.5m/s; severe valve calcification + peak velocity progression ≥ 0.3m/s per year; markedly elevated neurohormones (> threefold age-and sex-corrected normal range) without other explanation; severe pulmonary hypertension (systolic pulmonary artery pressure > 60 mmHG).
b See tables of recommendation in ESC/EACTS guidelines published here
In patients at increased surgical riska
CABG = Coronary Artery Bypass Grafting; CAD = Coronary Artery Disease; EuroSCORE = European System for Cardiac Operative Risk Evaluation; LV = Left Ventricle; SAVR = Surgical Aortic Valve Replacement; STS = Society of Thoracic Surgeons; TAVI = Transcatheter Aortic Valve Implantation; Frailty: Poor mobility, as assessed by the 6-minute walk test, and oxygen dependency are the main factors associated with increased mortality after TAVI and other VHD treatments. The assessment of frailty should not rely on a subjective approach, such as the ‘eyeball test’, but rather on a combination of different objective estimates.
a STS or EuroSCORE II ≥4% or logistic EuroSCORE I ≥10% or other risk factors not included in these scores such as frailty, porcelain aorta, sequelae of chest radiation
b Frailty: Poor mobility, as assessed by the 6-minute walk test, and oxygen dependency are the main factors associated with increased mortality after TAVI and other VHD treatments. The assessment of frailty should not rely on a subjective approach, such as the ‘eyeball test’, but rather on a combination of different objective estimates.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. June 10, 2014;129(23):2440-2492.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. June 20, 2017;135(25):e1159-e1195.
Baumgartner, H., et al. (2017).2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, Volume 38, Issue 36.21 September 2017. Pages 2739-2791. https://doi.org/10.1093/eurheartj/ehx391.
Disclaimer: This page may include information about products that may not be available in your region or country. Please consult the approved indications for use. Content on specific Medtronic products is not intended for users in markets that do not have authorization for use.